Compass Therapeutics (CMPX) Projected to Post Earnings on Thursday

Compass Therapeutics (NASDAQ:CMPX) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Compass Therapeutics to post earnings of ($0.10) per share for the quarter.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Trading Down 0.8 %

CMPX stock opened at $2.51 on Thursday. The company has a market cap of $347.09 million, a P/E ratio of -6.78 and a beta of 1.19. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08. The company’s 50-day moving average price is $2.77 and its 200 day moving average price is $2.03.

Analyst Upgrades and Downgrades

CMPX has been the topic of several recent research reports. Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target on the stock. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim initiated coverage on shares of Compass Therapeutics in a research report on Monday, February 24th. They set a “buy” rating and a $12.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.